Observational studyEuropean journal of clinical pharmacology2026
Influence of antihypertensive drug classes on circadian blood pressure patterns and left ventricular remodeling - a retrospective study.
Observational study in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircadian blood pressure (BP) abnormalities, including nondipping and reverse-dipping patterns, are increasingly recognized as major determinants of cardiovascular target-organ damage, independent of clinic BP. Antihypertensive drug classes and dosing time may differentially influence nocturnal BP control and left ventricular (LV) remodeling. However, real-world data integrating these factors remain limited, particularly in Chinesepopulations.
methodsThis retrospective, observational study included 500 adult patients with essential hypertension evaluated at a tertiary-care center between 2020 and 2024. All patients underwent valid 24-hour ambulatory BP monitoring (ABPM) and transthoracic echocardiography performed within six months of ABPM. Antihypertensive therapy was classified by drug class and dosing time (morning-only vs. evening/bedtime dosing of ≥ 1 agent). Circadian BP phenotypes were defined based on nocturnal systolic BP decline. LV mass index (LVMI) and LV geometric patterns were assessed according to standard echocardiographic criteria. Multivariable regression analyses were performed to evaluate associations between antihypertensive regimen, circadian BP indices, and LV remodeling.
resultsNondipping or reverse-dipping BP patterns were present in 48.6% of patients. RAAS-blocker-based regimens and bedtime dosing were associated with significantly lower nighttime BP, greater nocturnal BP decline, reduced morning BP surge, and a higher prevalence of preserved dipping compared with non-RAAS regimens and morning-only dosing (all p < 0.01). LV hypertrophy (LVH) was observed in 27.2% of patients and was significantly more prevalent among nondippers and reverse dippers. LVMI and relative wall thickness increased progressively with worsening circadian BP phenotype (p < 0.001). In multivariable models, nondipping (OR 1.89) and reverse dipping (OR 2.64), higher nighttime systolic BP, and nocturnal hypertension were independently associated with LVH. RAAS-based therapy and bedtime dosing were associated with lower odds of LVH, with partial attenuation after adjustment for nocturnal BP indices.
conclusionsIn treated hypertension, circadian BP abnormalities remain common and are strongly associated with adverse LV remodeling. Antihypertensive drug class and dosing time are important determinants of nocturnal BP control and cardiac structural changes, highlighting the clinical value of ABPM-guided, individualized treatment strategies.
Indexed as
Identifiers
42223692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.